July 12, 2010 - Actos Vastly Outsells Avandia In US.

The New York Times (7/12, Wilson) "Prescriptions" blog reported, "Avandia had lost a lot of ground in the market to Actos as a medicine for type 2 diabetes, even before the latest round of negative information as the Food and Drug Administration considers whether to order Avandia removed from the market." In 2009, according to IMS Health, "Avandia had $521 million in sales in the United States, compared to market leader Actos with $3.4 billion."